BBIO News and Press, BridgeBio Pharma Inc. From 10/24/23

2023-10-24 19:57:52 ET BridgeBio Pharma (NASDAQ: BBIO) had a good Tuesday on the stock exchange. Following the initiation of coverage by a veteran stock-tracking company, the commercial-stage biotech's share price experienced a nice boost to close the day more than 3% higher. That c...

2023-10-24 15:34:36 ET More on BridgeBio Pharma BridgeBio: Bets Acoramidis As The Pfizer Spoiler BridgeBio: Positive Updated Acoramidis Data May Not Imply Further Upside BridgeBio Pharma to issue 9.2M shares through PIPE financing BridgeBio heart drug meets p...

2023-10-13 18:11:38 ET Summary We rate Alnylam Pharmaceuticals, Inc.'s common stock a Buy on the dip after the complete response letter, CRL for Patisiran. The investment thesis is based on the high probability of success for Vutrisiran, the company's next-generation inverse RNA o...

2023-10-11 12:26:19 ET More on Alnylam Alnylam: FDA Rejection Of Onpattro For ATTR-CM Is A Setback, But A Manageable One Alnylam: Why The FDA Rejection Of Onpattro Is A Minor Setback Alnylam Continues To Deliver, But An Upcoming FDA Meeting Could Create Some Volatili...

PALO ALTO, Calif., Oct. 11, 2023 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on October 06, 2023, the compensation c...

2023-10-10 18:08:45 ET Summary Despite a positive panel recommendation, the FDA rejected the Alnylam Pharmaceuticals, Inc. application to market Onpattro for ATTR-CM, citing a lack of meaningful evidence of clinical efficacy. Amvuttra has always been the bigger opportunity in ATTR...

2023-10-10 14:48:17 ET Summary Alnylam's stock declined after the FDA issued a complete response letter citing inadequate evidence to support the efficacy of Onpattro in treating ATTR amyloidosis patients with cardiomyopathy. This is a minor setback because the HELIOS-B trial of A...

- In our study, encaleret restored physiologic mineral homeostasis in 13 participants with ADH1, specifically correcting hypocalcemia and reducing hypercalciuria - Rapid and sustained impact of encaleret on mineral homeostasis was observed, specifically in the normalization of blood cal...

- Early assessment of increased glycosylated ⍺DG levels at 3 months predicted subsequent ambulatory improvements at 9 months, supporting the use of glycosylated ⍺DG levels as a potential surrogate endpoint in LGDM2I/R9 - Long-term data from the ongoing Phase 2 study of BBP-4...

2023-10-06 18:09:48 ET Summary The biotechnology and pharmaceutical sectors have been under pressure in 2023, with the Invesco Pharmaceuticals ETF down 9% and the iShares Biotechnology ETF down 6%. Elevated interest rates and potential pricing power erosion are the primary headwin...